Medicus Pharma Announced Submission of Product Development Plan To The FDA To Treat External Squamous Cell Carcinoma (SCC) In Horses

Benzinga · 06/09 11:35

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive product development plan to treat external squamous cell carcinoma (SCC) under Investigational New Animal Drug (INAD File No.013880).